A Framework for Fitness-for-Purpose and Reuse in Computational Phenotyping
November 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ogen 1.25, Ogen 2.5, Ogen 5, Orhtho Est, Ogen 0.625
Synonyms :
Class :
Estrogens and related drugs; Estrogens
Brand Name :
Ogen 1.25, Ogen 2.5, Ogen 5, Orhtho Est, Ogen 0.625
Synonyms :
Class :
Estrogens and related drugs; Estrogens
Dosage forms & Strengths:
Adult:
Tablet:
0.75 mg
1.5 mg
3 mg
6 mg
Indicated for prevention of osteoporosis
0.75 mg orally each day for 25 days in a 31-day cycle
Adequate vitamin D and calcium should be the part of the hormonal therapy
Safety and efficacy are not seen in pediatrics
Indicated for prophylaxis of osteoporosis
0.75 mg orally each day for 25 days
Keep 6 days interval and repeat afterwards
may have a decreased diagnostic effect when combined with cosyntropin
may decrease the diagnostic effect when combined with metyrapone
cyproterone and ethinyl estradiol
may decrease the diagnostic effect of each other when combined
may decrease the therapeutic effect when combined with growth hormone analogs
may decrease the therapeutic effect when combined with growth hormone analogs
may decrease the therapeutic effect when combined with growth hormone analogs
may decrease the therapeutic effect when combined with growth hormone analogs
may increase the adverse effect
the therapeutic effect of anastrozole may be reduced by the use of estrogen derivatives
dehydroepiandrosterone may increase the adverse/toxic effects of estrogen derivatives
the therapeutic effect of exemestane may be reduced by the use of estrogen derivatives
the therapeutic effect of hemin may be reduced by the use of estrogen derivatives
may have an increased thrombogenic effect when combined with c1 inhibitors
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
It may reduce the effects when combined with pleurisy root by unspecified interactions mechanism
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
they decrease the effect of thyroid products
they decrease the effect of thyroid products
they decrease the effect of thyroid products
they decrease the effect of thyroid products
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may enhance the concentration of serum when combined with corticosteroids
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
human rabies immune globulin (HRIG)
may have an increased thrombogenic effect when combined with anthrax immune globulin
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
may enhance the concentration of serum when combined with corticosteroids
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
may diminish the therapeutic effect of ursodiol
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
may diminish the therapeutic effect of corticosteroids
may increase the serum concentration
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
It may enhance the thrombogenic activities when combined with sotrovimab
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
estrogen Derivatives may lower the effectiveness of chenodiol
estrogen derivatives can enhance the hepatotoxic effect of dantrolene
It may increase the thrombogenic effect when combined with C1 inhibitors
The combination of estrogen derivatives with ajmaline could potentially amplify its harmful and toxic effects
The therapeutic efficacy of guanethidine may be reduced by estrogen derivative
The concentration serum of melatonin may be intensified by estrogen derivative
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
the activity of estrogen pills may be reduced with agnus-castus
could lead to a reduction in the concentration serum of Hormonal Contraceptives
by altering metabolism, the concentration of cyanocobalamin may be reduced with estropipate
Frequency undefined:
Peripheral edema
Depression
Headache
Melasma
Bloating
Nausea & vomiting
Breast enlargement
Breast tenderness
Amenorrhea
Breakthrough bleeding
Spotting
Weight change
Corneal curvation change
Immunogenicity
Hypersensitivity reactions
Estropipate is contraindicated in patients hypersensitive to it or other components in the formulation.
Pregnancy consideration:
Category X
Breastfeeding warnings:
Estrogens are excreted in breast milk and hence should be taken with caution.
Pregnancy category:
Patient information leaflet
Generic Name: estropipate
Pronounced: es-troh-pi-paht
Why do we use estropipate?
Estropipate treats menopause and ovarian failure and helps in the prevention of osteoporosis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
